FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?

(2013) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches

(2012) Nicholas D Beyda et al.   ANNALS OF PHARMACOTHERAPY

The Presence of anFKSMutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

(2012) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011

(2012) A. A. Cleveland et al.   CLINICAL INFECTIOUS DISEASES

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values

(2012) M.A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Current perspectives on echinocandin class drugs

(2011) David S Perlin   Future Microbiology

Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes

(2011) D. N. Shah et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance

(2010) A. J. Zimbeck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CandidaBloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

(2010) Michael A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology of invasive candidiasis

(2010) Maiken C Arendrup   Current Opinion in Critical Care

Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

(2010) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

(2008) Brahm H. Segal et al.   CLINICAL INFECTIOUS DISEASES